Investigative Ophthalmology & Visual Science Cover Image for Volume 65, Issue 7
June 2024
Volume 65, Issue 7
Open Access
ARVO Annual Meeting Abstract  |   June 2024
SD-OCT Features and Macular Sensitivity in ABCA4-related Stargardt disease (STGD1)
Author Affiliations & Notes
  • Yanzhao WANG
    Wilmer Eye Institute, The Johns Hopkins University School of Medicine, Baltimore, Maryland, United States
  • Folahan Adesola Ibukun
    Wilmer Eye Institute, The Johns Hopkins University School of Medicine, Baltimore, Maryland, United States
  • Elias Traboulsi
    Cleveland Clinic Cole Eye Institute, Cleveland, Ohio, United States
  • David G Birch
    Retina Foundation of the Southwest, Dallas, Texas, United States
  • Janet S Sunness
    Greater Baltimore Medical Center, Baltimore, Maryland, United States
  • Rupert Strauss
    Department of Ophthalmology, Medizinische Universitat Graz Zentrenunabhangige Institute, Graz, Steierrmark, Austria
  • Isabelle S Audo
    Institut de la vision, Paris, Île-de-France, France
  • Michel Michaelides
    Moorfields Eye Hospital NHS Foundation Trust, London, London, United Kingdom
  • SriniVas R Sadda
    Doheny Eye Institute, Los Angeles, California, United States
  • Hendrik P Scholl
    Institute of Molecular and Clinical Ophthalmology Basel, Basel, Basel-Stadt, Switzerland
  • Eberhart Zrenner
    Eberhard Karls Universitat Tubingen, Tubingen, Baden-Württemberg, Germany
  • Michael S Ip
    Doheny Eye Institute, Los Angeles, California, United States
  • Artur V Cideciyan
    Scheie Eye Institute, Philadelphia, Pennsylvania, United States
  • Paul S Bernstein
    University of Utah Health John A Moran Eye Center, Salt Lake City, Utah, United States
  • Xiangrong Kong
    Wilmer Eye Institute, The Johns Hopkins University School of Medicine, Baltimore, Maryland, United States
  • Footnotes
    Commercial Relationships   Yanzhao WANG None; Folahan Ibukun None; Elias Traboulsi Travere Therapeutics, Code C (Consultant/Contractor), Sparing Vision, Code S (non-remunerative); David Birch Nacuity Pharmaceuticals, Editas, AGTC, PYC Therapeutics, ONL Therapeutics, Bluerock Therapeutics, Aldyra, Novartis, 4D Molecular Therapeutics, Inc., Foundation Fighting Blindness, , Code C (Consultant/Contractor), Biogen, AGTC, 4D Molecular Therapeutics Inc, PYC Therapeutics, Ocugen , Code F (Financial Support); Janet Sunness Lineage(OpRegen trial), Re-Vision Therapeutics , Code S (non-remunerative); Rupert Strauss None; Isabelle Audo Novartis, Janssen, Code C (Consultant/Contractor); Michel Michaelides MeiraGTx, Stargazer, Belite Bio, Mogrify, Code C (Consultant/Contractor), MeiraGTx, Code I (Personal Financial Interest), Stargazer, Belite Bio, MeiraGTx-Janssen, Code S (non-remunerative); SriniVas Sadda Apellis, Amgen, Abbvie/Allergan, Alexion, Samsung Bioepis, Biogen, Boerhinger Ingelheim, IvericBio, Novartis, Roche, Bayer, Regeneron, Pfizer, Astellas, Nanoscope, Jannsen, Centervue, Optos, Heidelberg NotalVision, Eyepoint, Character, OTx, Code C (Consultant/Contractor), Novartis, Roche, Optos, Heidelberg , Code R (Recipient), ARVO, Macula Scoiety, Code S (non-remunerative); Hendrik Scholl Alnylam Pharmaceuticals Inc.; Gerson Lehrman Group Inc.; Guidepoint Global, LLC; and Tenpoint Therapeutics., Code C (Consultant/Contractor), Swiss National Science Foundation, the Wellcome Trust, the Foundation Fighting Blindness Clinical Research Institute, Code F (Financial Support), Ascidian Therapeutics, Inc.; Boehringer Ingelheim Pharma GmbH & Co; Droia NV; Eluminex Biosciences; Gyroscope Therapeutics Ltd.; Janssen Research & Development, LLC (Johnson & Johnson); Okuvision GmbH; ReVision Therapeutics Inc.; and Saliogen Therapeutics Inc,Belite Bio, F. Hoffmann-La Roche Ltd, ViGeneron, Steering Committee of Novo Nordisk , Code S (non-remunerative); Eberhart Zrenner None; Michael Ip Alimera, Allergan, Amgen, Apellis, Clearside Biomedical, Genentech, IVERIC Bio, Novartis, Regeneron, Regenxbio, Code C (Consultant/Contractor), Apellis, Biogen, Genentech, IVERIC Bio, Lineage Cell Therapeutics, ONL Therapeutics, Regenxbio, 4DMT, Code F (Financial Support); Artur Cideciyan None; Paul Bernstein None; Xiangrong Kong None
  • Footnotes
    Support  R21EY032955
Investigative Ophthalmology & Visual Science June 2024, Vol.65, 975. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Yanzhao WANG, Folahan Adesola Ibukun, Elias Traboulsi, David G Birch, Janet S Sunness, Rupert Strauss, Isabelle S Audo, Michel Michaelides, SriniVas R Sadda, Hendrik P Scholl, Eberhart Zrenner, Michael S Ip, Artur V Cideciyan, Paul S Bernstein, Xiangrong Kong; SD-OCT Features and Macular Sensitivity in ABCA4-related Stargardt disease (STGD1). Invest. Ophthalmol. Vis. Sci. 2024;65(7):975.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : To assess the association between structural parameters on SD-OCT and macular function measured by microperimetry in STGD1.

Methods : Baseline data from the multicenter natural history ProgStar-study of STGD1 were analyzed. From SD-OCT images the study reading center measured the thickness of the inner retina (IR), outer nuclear layer (ONL), inner and outer segments (IS, OS) and RPE thicknesses in the ETDRS central subfield (CS), inner ring (INR) and outer ring (OR). Macular sensitivity (MS) was assessed at 68 loci in the central 20° using the Nidek MP-1 device, and average sensitivities by ETDRS subfield were categorized as absolute scotoma (0dB), relative scotoma (<12dB), or relatively normal (≥12dB). Generalized logistic regressions estimated structure-function relationships.

Results : Of the 198 patients analyzed (324 eyes where their MS were centered at the fovea), 58% were female, 88% were white, with median age 23 years. 53% had absolute scotoma (average MS=0) in the central subfield, 15% in inner ring, and 1% in outer ring. In the central subfield, 39%, 84%, and 83% of eyes had complete loss of RPE, OS, and IS, respectively. Multiple regression including thickness of all layers estimated complete loss of (IS+OS) thickness was associated with 62.5 higher odds of absolute scotoma versus relatively normal sensitivity (95%CI:10 - 409, p<0.001). In the inner ring, thinner (IS+OS) and RPE was associated with higher odds of absolute scotoma versus relatively normal sensitivity (odds ratio: 5.7(p=0.007), 1.2(p=0.002), respectively). In the outer ring, every 1 µm thinner (IS+OS) was associated with 1.7 (p<0.001) higher odds of relative scotoma versus relatively normal sensitivity. Figure 1 shows absolute scotoma corresponded to thinner RPE, IS, OS and ONL. Complete loss of photoreceptor IS+OS in the central subfield was strongly associated with foveal absolute scotoma. In the inner ring, both photoreceptor and RPE thicknesses correlated with absolute scotoma. In the outer ring, the absolute scotoma subgroup demonstrates increased inner retina thickness.

Conclusions : When developing therapeutic molecules or approaches to treat Stargardt disease, it is necessary to evaluate the effect of the potential therapy on preserving both RPE and photoreceptors.

This abstract was presented at the 2024 ARVO Annual Meeting, held in Seattle, WA, May 5-9, 2024.

 

Figure 1 Heatmap Representation of Layer Thickness Variation Across Sensitivity Categories by Layer and Subfield

Figure 1 Heatmap Representation of Layer Thickness Variation Across Sensitivity Categories by Layer and Subfield

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×